Related Experiment Videos
CSF phosphorylated tau protein and mild cognitive impairment: a prospective study
1Department of Geriatric Medicine, Tohoku University School of Medicine, Sendai, Miyagi, 980-8574, Japan.
Experimental Neurology
|October 14, 2000
Summary
Cerebrospinal fluid phospho-tau and total-tau levels can predict Alzheimer's disease (AD) development in mild cognitive impairment (MCI) patients. Elevated levels indicate early AD pathology, suggesting neurodegeneration may begin when MCI symptoms first appear.
Area of Science:
- Neuroscience
- Biochemistry
Background:
- Mild cognitive impairment (MCI) is a transitional stage between normal aging and Alzheimer's disease (AD).
- Biomarkers for early AD detection are crucial for timely intervention and disease management.
Purpose of the Study:
- To investigate the utility of cerebrospinal fluid (CSF) phosphorylated tau (phospho-tau) and total tau (total-tau) in predicting AD development in MCI patients.
- To assess these CSF markers in individuals with subjective memory complaints but no objective cognitive decline.
Main Methods:
- Quantification of CSF phospho-tau (Thr231/Ser235) and CSF total-tau using sandwich ELISA.
- Analysis of 20 MCI patients who progressed to AD and 7 healthy memory complainers.
Main Results:
- 65% of MCI patients who developed AD exhibited high CSF total-tau and detectable CSF phospho-tau.
- All memory complainers showed low or undetectable levels of both CSF markers.
- Elevated tau markers in MCI suggest early AD pathological changes.
Conclusions:
- CSF phospho-tau and total-tau are valuable predictors of AD progression in MCI.
- Abnormal tau accumulation and neurodegeneration may occur early in the symptomatic phase of MCI.
- These biomarkers can aid in identifying individuals at high risk for AD.